Variants Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

<p>A new study by investigators from <a href="https://www.massgeneralbrigham.org/">Mass General Brigham</a> found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test&mdash;a phenomenon known as virologic rebound. By contrast, people not taking Paxlovid only experienced rebound about 2 percent of the time. Results are published in <a href="...

  At a glance: New study shows that viral rebound with Paxlovid is more common than previously believed. Clinicians should counsel patients about the possible risk of transmitting virus during rebound. A new study by Harvard Medical School researchers at Massachusetts General Hospital and Brigham and Women’s Hospital has found that one in five individuals […]

Though antivirals are critical for reducing severe COVID-19 symptoms, researchers suggested that the medication may not always be needed for milder cases.